3.5. Safety
SAEs, injection-site reaction, neutropenia
VIRAL UPPER RESPIRATORY TRACT INFECTIONS, NEUTROPENIA
In the primary analysis of QUEST, the overall rates of TEAEs were similar in the combined placebo (83.1%) and dupilumab (81.0%) groups (SAEs, 8.4% and 8.2%, respectively). The most frequent AE occurring in ≥5% of patients and at higher rates among patients who received dupilumab was injection-site reaction (16.8% of patients in combined dupilumab vs. 7.9% in combined placebo groups). Viral upper respiratory tract infections (URTI) were the next most frequent AE in all groups [In patients with and without neutropenia, as analyzed here, overall rates of TEAEs and SAEs also were similar between dupilumab and placebo (Tables 